LIVN Stock Analysis — LivaNova PLC
Sector: Healthcare
AI Verdict
LivaNova trades at 16.9x next year's earnings with 10.7% growth, making it cheap for the sector if its clinical moat holds, but the value case depends on sustaining that growth.
Competitive Moat
LivaNova specializes in neuromodulation and cardiac surgery devices, with a defensible position in vagus nerve stimulation for epilepsy and depression. Their moat is built on FDA-approved devices and clinical data that create high switching costs for hospitals and physicians.
Summary
LivaNova's growth is driven by its established neuromodulation device platform in a regulated medical device niche.
Where It Stands
The stock trades at 16.9x next year's earnings, a discount to the healthcare sector median of 22x, while posting 10.7% trailing revenue growth.
Key Metrics
- Forward P/E: 16.9x
- Revenue Growth: +0.1%
- 52-Week High: $71.92
- 52-Week Low: $39.36
Analyst Consensus
13 Buy · 4 Hold · 0 Sell (17 analysts)
Bull Case
A 16.9x forward P/E gives you exposure to double-digit (10.7%) revenue growth at a below-sector-median price.
Bear Case
If the P/E reverts to the sector median of 22x, there's little room for multiple expansion, limiting upside if growth slows below 10.7%.
Catalyst to Watch
Watch for FDA approvals or pivotal trial results, as positive outcomes could justify a higher P/E multiple.